RFA-TR-23-010: Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on May 22, 2023.
From the official notice on Grants.gov, last changed April 14, 2023. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR21
- Clinical trialsNot allowed
- Funded byNINDS, NIDCR, NIDA
- Median yearly award$419,375
- Typical project length2.5 years
- R21, Exploratory/Developmental Research Grant. Early, exploratory ideas that may not have preliminary data yet, usually for up to two years. Other open R21 notices.
Projects funded under RFA-TR-23-010 were run by National Institute of Neurological Disorders and Stroke (NINDS, 3 projects), National Institute of Dental and Craniofacial Research (NIDCR, 2 projects), National Institute on Drug Abuse (NIDA, 1 project) and National Institute on Aging (NIA, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-TR-23-010 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| RFA-TR-22-011 | January 20, 2022 | Closed April 17, 2023 | Closed |
Key dates
| Posted | April 14, 2023 |
|---|---|
| Deadline | May 22, 2023 |
| Archived by Grants.gov | June 27, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Is this a realistic fit?
- Most of the money in the 9 programs behind this notice (74% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
NCATS is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS. Please see Determination that a Public Health Emergency Exists Nationwide as the Result of the Opioid Crisis as renewed in Renewal of the Determination that a Public Health Emergency Exists Nationwide as the Result of the Continued Consequences of the Opioid Crisis. The purpose of this funding opportunity announcement (FOA) is to support early-stage research projects focusing on the identification of new druggable targets for pain, opioid use disorder and/or overdose within the understudied druggable proteome. This FOA is part of the NIH Helping to End Addiction Long Term (HEAL) initiative to accelerate the development of novel medications to treat all aspects of the opioid addiction cycle, including progression to chronic use, withdrawal symptoms, craving, relapse, and overdose.
Funded under RFA-TR-23-010 so far
NIH funded 7 projects under RFA-TR-23-010 in fiscal 2024, at 6 institutions. The median yearly award was $419,375.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Targeting GTP Cyclohydrolase 1 for treating chronic orofacial pain | University of Florida | 2024 | $27,063 |
| Role of Scn1b in Susceptibility to Neuropathic Pain | University of California Berkeley | 2024 | $415,519 |
| The potential benefits of autophagy activator TFEB in opioid use disorder in mice | Florida International University | 2024 | $405,625 |
| Exploring the unknown function of LRRC55 in pain | Duke University | 2024 | $444,125 |
| Binding NF-κB essential modulator (NEMO) to Treat Surgical Pain | Stanford University | 2024 | $427,187 |
| The involvement of GPR37L1 on a chronic migraine-like state | Florida Atlantic University | 2024 | $419,375 |
| Role of Understudied aGPCRs in Orofacial Neuropathic Pain | University of Florida | 2024 | $419,375 |
Who has won Aging Research grants before
From fiscal 2021 to 2025, Aging Research (93.866) awarded $19 billion across 11,026 grant awards, an average of $1.7 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Regents of the University of California, San Francisco | California | 337 | $575 million |
| The Trustees of Columbia University in the City of New York | New York | 242 | $574 million |
| University of Southern California | California | 203 | $572 million |
| The Washington University | Missouri | 210 | $556 million |
| Regents of the University of Michigan | Michigan | 232 | $538 million |
Who has won Extramural Research Programs in the Neurosciences and Neurological Disorders grants before
From fiscal 2021 to 2025, Extramural Research Programs in the Neurosciences and Neurological Disorders (93.853) awarded $9.1 billion across 8,641 grant awards, an average of $1.0 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The General Hospital Corporation | Massachusetts | 203 | $288 million |
| The Regents of the University of California, San Francisco | California | 248 | $277 million |
| The Johns Hopkins University | Maryland | 230 | $276 million |
| The Trustees of Columbia University in the City of New York | New York | 188 | $226 million |
| Regents of the University of Michigan | Michigan | 179 | $221 million |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Other programs behind this notice
- Child Health and Human Development Extramural Research
- National Center for Advancing Translational Sciences
- Arthritis, Musculoskeletal and Skin Diseases Research
- Alcohol Research Programs
- Oral Diseases and Disorders Research
- Research and Training in Complementary and Integrative Health
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-TR-23-010 still open?
No. It closed on May 22, 2023.
Who can apply for Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Emergency Awards: HEAL Initiative-Early-Stage Discovery of New Pain and Opioid Use Disorder Targets Within the Understudied Druggable Proteome (R21 Clinical Trial Not Allowed)?
Closed May 22, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-TR-23-010?
NIH RePORTER lists 7 projects funded under RFA-TR-23-010 in fiscal 2024, at 6 institutions. The most were at University of Florida, University of California Berkeley, Florida International University.
Who has won Oral Diseases and Disorders Research grants before?
The largest recipients over five fiscal years were Regents of the University of Michigan, The Regents of the University of California, San Francisco, University of Southern California. The program made 2,263 awards worth $1.9 billion in that time.
Similar open grants
- Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)
- New Approaches for Measuring Brain Changes Across Longer Timespans (R21 Clinical Trial Optional)
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional)